Improving Decision-Making Processes in Health: Is It Time for (Disease-Specific) Reference Models? Hossein Haji Ali AfzaliLaura BojkeJonathan Karnon Editorial 20 August 2019 Pages: 1 - 4
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab Caridad PontesCorinne ZaraBrian Godman Current Opinion 07 November 2019 Pages: 5 - 16
Determining the Baseline Strategy in a Cost-Effectiveness Analysis with Treatment Sequences Marta Giulia ViolaAlexander Diamantopoulos Practical Application 20 September 2019 Pages: 17 - 29
Using the Threshold Technique to Elicit Patient Preferences: An Introduction to the Method and an Overview of Existing Empirical Applications Brett HauberJoshua Coulter Review Article 20 September 2019 Pages: 31 - 46
Price Models for Multi-indication Drugs: A Systematic Review Carlos Campillo-ArteroJaume Puig-JunoyMarta Trapero-Bertran Systematic Review 16 September 2019 Pages: 47 - 56
Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System Ângela J. BenJeruza L. NeyeloffCristina R. Neumann Original Research Article Open access 01 November 2019 Pages: 57 - 68
A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance David J. MottGrace HampsonMichael M. Hopkins Original Research Article Open access 20 September 2019 Pages: 69 - 79
Why Do Informal Sector Workers Not Pay the Premium Regularly? Evidence from the National Health Insurance System in Indonesia Teguh DartantoAlin HalimatussadiahRooswanti Soeharno Original Research Article 18 September 2019 Pages: 81 - 96
Estimating Attribute-Specific Willingness-to-Pay Values from a Health Care Contingent Valuation Study: A Best–Worst Choice Approach Ivan SeverMiroslav VerbičEva Klaric Sever Original Research Article 28 September 2019 Pages: 97 - 107
Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany Afschin GandjourDennis A. Ostwald Original Research Article 07 November 2019 Pages: 109 - 125
Forecasting Ontario Oncology Drug Expenditures: A Hybrid Approach to Improving Accuracy Paula M. MurrayYusuf A. ShalabyJessica Arias Original Research Article 14 November 2019 Pages: 127 - 137
Comment on: “Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018–2040” Muhammad Radzi Abu HassanHuan-Keat Chan Letter to the Editor 19 December 2019 Pages: 139 - 140
Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands Renée Else MichelsMaria De FrancescoMarieke Krol Correction Open access 14 January 2020 Pages: 141 - 141